TITLE

HIGHER DOSES OF INTERFERON BETA-1A GIVE NO ADDED BENEFIT

PUB. DATE
January 2001
SOURCE
Worldwide Biotech;Jan2001, Vol. 13 Issue 1, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the results of a clinical test by Biogen Inc. on Avonex (Interferon beta-1a) which is equally effective if administered whether in low or high dosages in reducing disability progression.
ACCESSION #
4060562

 

Related Articles

  • Genzyme to commercialize and distribute Biogen's Avonex.  // Chemical Market Reporter;09/14/98, Vol. 254 Issue 11, p43 

    Reports that Genzyme General and Biogen Inc. have entered into an agreement under which Genzyme will commercialize and exclusively distribute Biogen's interferon beta-la product, Avonex in Japan.

  • Biogen Wins Round IN Avonex Litigation.  // Chemical Market Reporter;08/21/2000, Vol. 258 Issue 8, p20 

    Reports on a victory won by Biogen Inc. in patent litigation filed by Berlex Laboratories concerning its interferon beta-1a drug Avonex. Usage of Avonex and Berlex's Betaferon; Court's ruling on the case; Avonex sales of 1999.

  • Biogen patent revoked.  // Chemical Market Reporter;04/14/97, Vol. 251 Issue 15, p5 

    Reports that the Technical Board of Appeals of the European Patent Office (EPO) has revoked Biogen Inc.'s European patent for the production of recombinant beta interferon. Reasons for the revocation.

  • Training in self injection is essential.  // Inside MS;Fall96, Vol. 14 Issue 3, p6 

    Focuses on the importance of self-injection training for the application of Avonex. Video and handbook prepared by Biogen; Hands-on training session.

  • Biogen Moves Into Europe.  // Chemical Market Reporter;5/21/2001, Vol. 259 Issue 21, p3 

    Reports on the investment of Biogen Inc. to construct its first major European manufacturing facility in Hillerod, Denmark. What the facility will include; Comments from company's President James C. Mullen about the facility.

  • Biogen Reports Strong 2Q Results as It Battles with Serono over MS Drug. Krause, Carey // Chemical Market Reporter;7/23/2001, Vol. 260 Issue 4, p8 

    Reports on the growth of Biogen Inc. in the second quarter of 2001. Biogen's earnings per share in the second quarter of 2001; Sales the company is targeting in year 2001; Competition between Biogen and Serono to gain share of the market for relapse-remitting multiple sclerosis.

  • Biogen Posts Solid First Quarter Earnings.  // Chemical Market Reporter;4/28/2003, Vol. 263 Issue 17, p12 

    Reports on the financial performance of pharmaceutical company Biogen Inc. in the first quarter of 2003. Earnings; Increase in underlying profit; Market performance of various brands.

  • Biogen's Big Picture. Shalo, Sibyl // Pharmaceutical Executive;Jan2003, Vol. 23 Issue 1, p34 

    Profiles James Mullen, president and chief executive officer of the Biogen, a global biotechnology company. Predecessor; Management style; Business and operational changes implemented for the company.

  • Biogen Breaks Ground for Manufacturing Facility in Denmark.  // PM Network;Jul2003, Vol. 17 Issue 7, p13 

    Reports on the construction of Biogen's manufacturing facility in Denmark. Bioreactor capacity of the facility; Cost of the project; Number of jobs that will be created for the facility.

  • The Future of Filtration in Biomaterials Processing. Pickering, Lulu // Drug Discovery & Development;Oct2002, Vol. 5 Issue 9, p71 

    Discusses the importance of filtration technology in biomanufacturing process. Use of filters to remove virus and bacterial contamination; Estimated cost of hardware needed to operate filtration systems; Types of filters used by Cambridge, Massachusetts-based Biogen Inc. in the biomanufacturing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics